Daniel Pallin, MD, MPH - Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy –Related Adverse Effects in the Emergency Department
Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department (Source: Peerview CME/CE Video Podcast - Internal Medicine International)
Source: Peerview CME/CE Video Podcast - Internal Medicine International - November 30, 2018 Category: Internal Medicine Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
Daniel Pallin, MD, MPH - Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy –Related Adverse Effects in the Emergency Department
Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department (Source: PeerView CME/CE Video Podcast - Oncology)
Source: PeerView CME/CE Video Podcast - Oncology - November 30, 2018 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
NCI Workshop on Cell-based Immunotherapy for Solid Tumors (Day 2)
At this workshop, the NCI invites the extramural community to inform the NCI regarding the current state of preclinical and clinical development for cell-based immunotherapies for cancer. NCI and extramural investigators will discuss the newest innovations to advance cell-based immunotherapy with regard to making this treatment modality easier to manufacture and more efficacious against a variety of solid tumors. Future directions of the field from the perspective of developing better technologies to conducting clinical trials will be discussed as knowledge and resource gaps are identified. The workshop will provide knowle...
Source: Videocast - All Events - November 26, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
NCI Workshop on Cell-based Immunotherapy for Solid Tumors (Day 1)
At this workshop, the NCI invites the extramural community to inform the NCI regarding the current state of preclinical and clinical development for cell-based immunotherapies for cancer. NCI and extramural investigators will discuss the newest innovations to advance cell-based immunotherapy with regard to making this treatment modality easier to manufacture and more efficacious against a variety of solid tumors. Future directions of the field from the perspective of developing better technologies to conducting clinical trials will be discussed as knowledge and resource gaps are identified. The workshop will provide knowle...
Source: Videocast - All Events - November 26, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
Defining mechanisms of pathogenesis in cutaneous leishmaniasis to develop new approaches to therapy
IIG Seminar
Phil Scott received his Ph.D. from the University of Pennsylvania in 1980 where he studied immunoregulatory mechanisms in experimental cutaneous leishmaniasis, and from there went to Dr. Alan Sher ’ s laboratory at NIH where he defined the role of CD4+ Th1 and Th2 cells in controlling leishmaniasis. He left NIH in 1989 to return to Penn, and rose through the ranks to become Professor of Immunology in 1995. During his time at Penn he served for 12 years as Chair of the Department of Pathobiology in the School of Veterinary Medicine, and is currently Vice Dean for Research& Academic Resources. Dr. Scott ’ s c...
Source: Videocast - All Events - November 26, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
CCR Eminent Lecture: The Multifaceted Function of the PD-1 Pathway
NCI Center for Cancer Research Eminent Lecture
Arlene Sharpe is the George Fabyan Professor of Comparative Pathology, Head of the Division of Immunology and Interim Co-Chair of the Department of Microbiology and Immunobiology at Harvard Medical School. She is a member of the Department of Pathology at Brigham and Women ’ s Hospital, an Associate Member at the Broad Institute of MIT and Harvard, Leader of the Cancer Immunology Program at the Dana-Farber/Harvard Cancer Center and Co-Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women ’ s Hospital.
Dr. Sharpe earned h...
Source: Videocast - All Events - September 18, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
Sounding the Alarm and Putting Out the Fire: New Mechanistic Insights into Inflammation Triggered by Invasive Infection
NIH Director ’ s Wednesday Afternoon Lecture Series
The Lieberman laboratory studies cytotoxic T lymphocytes and their role in infection and tumor immunity. They study the molecular pathways used by killer lymphocytes and their cytotoxic granule proteases, called granzymes, and pore-forming proteins, perforin and granulysin, to induce programmed cell death. They have defined a caspase-independent programmed cell death pathway activated by granzyme A. Recent work has identified an unexpected role for granzymes and granulysin in protection against bacteria and parasites. They recently uncovered the molecular basis for infl...
Source: Videocast - All Events - May 23, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
Ezra Cohen, MD, FRCPC, FASCO - Solving the Multimodal Puzzle of Head & Neck Cancer in the Immunotherapy Era: How Evidence is Driving Practice Changes
Solving the Multimodal Puzzle of Head & Neck Cancer in the Immunotherapy Era: How Evidence is Driving Practice Changes (Source: Peerview CME/CE Video Podcast - Internal Medicine International)
Source: Peerview CME/CE Video Podcast - Internal Medicine International - April 25, 2018 Category: Internal Medicine Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
Ezra Cohen, MD, FRCPC, FASCO - Solving the Multimodal Puzzle of Head & Neck Cancer in the Immunotherapy Era: How Evidence is Driving Practice Changes
Solving the Multimodal Puzzle of Head & Neck Cancer in the Immunotherapy Era: How Evidence is Driving Practice Changes (Source: PeerView CME/CE Video Podcast - Oncology)
Source: PeerView CME/CE Video Podcast - Oncology - April 25, 2018 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
B cells in Autoimmune diseases: Focus on Sj ö gren's Syndrome
NIDCR Clinical Research Fellowship Grand Rounds
B cells play a complex role in the development of systemic autoimmune diseases, especially in primary Sj ö gren's syndrome, a progressive condition that damages saliva and tear glands and leads to dry mouth, dry eyes, and other symptoms. Dr. Jacques-Olivier Pers will outline growing evidence that regulatory B lymphocytes (Breg) may blunt the pathogenesis of systemic autoimmune disease, and thus may be potential targets for treatment. Studies of distinct B cell subsets that play differing roles in autoimmune diseases are providing new insights into Breg development and immune...
Source: Videocast - All Events - April 11, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
Naiyer Rizvi, MD - Moving in Leaps and Bounds Towards Precision Immuno-Oncology: Latest Biomarker Strategies to Guide Patient Selection and Maximize the Potential of Cancer Immunotherapies
Moving in Leaps and Bounds Towards Precision Immuno-Oncology: Latest Biomarker Strategies to Guide Patient Selection and Maximize the Potential of Cancer Immunotherapies (Source: Peerview CME/CE Video Podcast - Internal Medicine International)
Source: Peerview CME/CE Video Podcast - Internal Medicine International - April 4, 2018 Category: Internal Medicine Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
Naiyer Rizvi, MD - Moving in Leaps and Bounds Towards Precision Immuno-Oncology: Latest Biomarker Strategies to Guide Patient Selection and Maximize the Potential of Cancer Immunotherapies
Moving in Leaps and Bounds Towards Precision Immuno-Oncology: Latest Biomarker Strategies to Guide Patient Selection and Maximize the Potential of Cancer Immunotherapies (Source: PeerView CME/CE Video Podcast - Oncology)
Source: PeerView CME/CE Video Podcast - Oncology - April 4, 2018 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
Autoimmunity, Cancer and Immunology (Day 2)
This meeting will focus on 2 issues and will include speakers from the NIH intramural and extramural communities:
Understanding the biology of immune-related adverse events which have occurred in cancer patients being treated with immunotherapies and how that might inform the study of autoimmune disease.
Defining the potential for the study of autoimmune disease to lead to greater understanding of the treatment and management of immune-related adverse events during and following cancer therapies.For more information go tohttps://ncifrederick.cancer.gov/events/CicAutoimmune2018/default.aspAir date: 3/23/2018 8:00:00 AM ...
Source: Videocast - All Events - March 19, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
Autoimmunity, Cancer and Immunology (Day 1)
This meeting will focus on 2 issues and will include speakers from the NIH intramural and extramural communities:
Understanding the biology of immune-related adverse events which have occurred in cancer patients being treated with immunotherapies and how that might inform the study of autoimmune disease.
Defining the potential for the study of autoimmune disease to lead to greater understanding of the treatment and management of immune-related adverse events during and following cancer therapies.For more information go tohttps://ncifrederick.cancer.gov/events/CicAutoimmune2018/default.aspAir date: 3/22/2018 8:00:00 AM ...
Source: Videocast - All Events - March 19, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
PD-1 Cancer Immunotherapy
NCI Center for Cancer Research Eminent Lecture Series
Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School. Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University. His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28).
In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus def...
Source: Videocast - All Events - March 16, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
